Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer

Breast Neoplasms Clinical Trial

Official title:

A Phase II Randomized Study of Physiological (6 mg Daily) and High Dose (30 mg Daily) Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00324259
• Other study ID #: 04-0412 / 201108392
• Status: Completed
• Phase: Phase 2
• First received: May 8, 2006
• Last updated: January 29, 2015
• Start date: August 2004
• Est. completion date: August 2014

Study information

• Verified date: January 2015
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This study aims to examine whether estradiol is an appropriate for future Phase 3 studies as second or third line endocrine treatment. In addition the protocol explores several approaches to enhance the safety of estrogen therapy, including the establishment of the efficacy of a lower dose than that currently recommended and through the early identification of non-responders to avoid drug exposure in patients who are unlikely to benefit to estrogen treatment.

Description:

The purpose of this study is to compare the effects of two doses (6 mg and 30 mg) of Estradiol, a type of estrogen. This and other forms of estrogen used at doses much higher than those used for postmenopausal hormone replacement therapy have been shown to cause tumor growth stabilization or shrinkage in patients with breast cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 66
• Est. completion date: August 2014
• Est. primary completion date: March 2011
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Postmenopausal women with advanced hormone receptor positive (ER and or PgR) breast cancer, has received prior treatment with an aromatase inhibitor in the advanced disease setting, and experienced at least 24 weeks of progression free survival. As long as the patient experienced an aromatase inhibitor response as defined this way, she is still eligible even if she has received further lines of endocrine therapy, which may include other aromatase inhibitors or tamoxifen, even if these subsequent lines of treatment were unsuccessful (see below for permitted chemotherapy and trastuzumab therapy).

OR

• Postmenopausal women with systemic or unresectable local relapse after taking at least two years of adjuvant aromatase inhibitor therapy.

• Clinical diagnosis of postmenopausal status is defined as either:

1. Age greater than 50 years and amenorrhea for 1 year

2. Bilateral Surgical ovariectomy

3. Serum FSH and estradiol level in the postmenopausal range before the initiation of AI therapy.

4. If the patient was receiving an LHRH agonist to maintain a postmenopausal state during AI therapy this should be continued since recovery of menses would lead to uncontrolled estrogen exposure and pregnancy during estrogen therapy is contraindicated.

• Tumor cell expression of ER and/or PgR can be ascertained on either the primary or the metastatic site. However when both types of tissue are available, the metastatic site should be used to determine eligibility. ER and/or PgR positive are defined as at least 10% of malignant cells with positive nuclear staining.

• The patients may have received adjuvant and/or neoadjuvant chemotherapy.

• Prior radiotherapy is permitted as long as it was planned before the start of the study medication and is completed within 3 weeks of trial medication starting.

• Prior tamoxifen therapy is also permitted as adjuvant or advanced disease therapy.

• Patients with ER+ HER2+ disease are eligible even of they have received trastuzumab in the past (and even if it was administered in combination with endocrine treatment) as long as they meet all other eligibility criteria. Trastuzumab therapy must be held during estradiol treatment.

• Use of prior experimental agents alone or in combination with endocrine therapy is also permissible, but a wash out of one month is required if the immediate prior therapy involved a study medication that had not been subject to regulatory approval.

• Prior adjuvant chemotherapy is permitted as well as one line of chemotherapy for advanced disease.

• Patient must have at least one measurable lesion defined by RECIST criteria. To be considered measurable, a baseline lesion must have a minimum diameter to compensate for measurement error: 1 cm for soft tissue lesions, 1 cm for lung lesions including pleural lesions measured by CT scan, 1 cm for liver lesions measured by CT scan.

• Patients with bone only disease can also be enrolled if they meet the following criteria:

1. Four or more lesions more than one cm, measurable on CT scan bone windows.

2. At least one tumor marker that is elevated to at least two times the upper limit of normal.

3. All patients should have a baseline bone scan with X-ray evaluation of all hot spots, CT chest abdomen and pelvis (with bone windows), and tumor marker assessment. Also CT scan of the extremities should be done on suspicious areas seen on X-ray evaluation of all hot spots if these extremity lesions are to be followed for response.

• The patient must have an ECOG performance status of 0-2

• The patient should have a life expectancy of > 6 months.

• The patient must have adequate hematologic function, defined as ANC >1000/mm3 and platelets > 75,000/mm3.

• The patient must have adequate renal function, defined as serum creatinine less than or equal to 1.5 times the upper limit of normal.

• The patient must have adequate liver function defined as serum bilirubin less than or equal to 1.5 times the upper limit of normal (three times the upper limit of normal for patients with hereditary benign hyperbilirubinaemia), transaminases (ALT, AST) less than or equal to 2.5 times the upper limit of normal in patients without liver metastasis or less than or equal to 5 times the upper limit of normal in patients with liver metastasis.

• For patients with bone metastasis, treatment with i.v. bisphosphonates during the trial is mandatory because of the risk of hypercalcemia. Bisphosphonate therapy must be started before the patient begins protocol therapy.

• Preexisting hypercalcemia should be treated and calcium normalized prior to study entry.

• The patient must give written informed consent prior to initiation of any invasive study-related procedures that would otherwise not be performed, and must be able to comply with scheduled visits and evaluations.

• Inclusion of Women and Minorities: Entry to this study is open to women of all racial and ethnic subgroups.

• Patients with fasting blood glucose level = 200 mg/dL. If greater, hyperglycemia must be treated before initiation of study investigations.

Exclusion Criteria:

• Patients with CNS involvement with metastatic breast cancer or life threatening lymphangitic or large volume lung or liver disease that threatens organ function.

• Patients with history of deep venous thrombosis, pulmonary embolism, stroke, acute myocardial infarction, congestive cardiac failure, untreated hypertension.

• Ischemic changes on a baseline EKG or other evidence of ischemic heart disease.

• Undiagnosed abnormal genital bleeding

• Untreated cholelithiasis

• Fasting serum triglycerides greater than 400. Patients should be treated and triglycerides controlled prior to study entry.

• Treatment with fulvestrant within 12 months of study initiation (fulvestrant has been shown to antagonize estradiol induced apoptosis in preclinical models (5).

• The patient's only qualifying lesion (s) have been previously irradiated or are scheduled for irradiation following study entry.

• Severe or uncontrolled concomitant disease from other causes.

• EGOG Performance status 3 or 4.

• The patient has previous malignancies other than breast cancer except a) adequately treated in situ carcinoma of the cervix, b) localized basal or squamous cell carcinoma of the skin c) any previous malignancy treated with curative intent with a recurrence risk of less than 30%.

• The patient is unable to understand the informed consent or is unlikely to be compliant with the protocol.

• More than one line of palliative chemotherapy for advanced disease.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Neoplasms

Intervention

Drug:
• Estradiol

Locations

Country	Name	City	State
United States	University of North Carolina Breast Clinic	Chapel Hill	North Carolina
United States	University of Chicago	Chicago	Illinois
United States	Case Western University	Cleveland	Ohio
United States	Cleveland Clinic, Lerner College of Medicine, Case Western Reserve University	Cleveland	Ohio
United States	Duke University Medical Center	Durham	North Carolina
United States	Memorial Sloan-Kettering Cancer Center	New York	New York
United States	Washington University School of Medicine	St. Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical Benefit Rate (CR Plus PR Plus SD)	Complete response (CR) + partial response (PR) + stable disease (SD) using RECIST 1.0; CR = disappearance of all target lesions; PR = at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter; SD = neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for progressive disease; SD is defined as lack of disease progression by 24 weeks.	24 weeks after start of treatment	No
Secondary	Progression-free Survival (PFS)	Defined as the time from treatment initiation to disease progression or death.; Time of last observation for patients remaining in the study and the time at which dose reductions, study drug termination, and withdrawal of consent occurred were treated as censored data.; Indicated as number of participants who had not progressed at 12 weeks, 24 weeks, 36 weeks, and 48 weeks.; Progression per RECIST 1.0 = at least a 20% increase in the sum of the longest diameter of target lesions taking as references the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.	Up to 48 weeks	No
Secondary	Quality of Life	Surveyed using a 6 item estrogen adverse effect questionnaire (headaches, bloating, breast tenderness, retention of fluid, nausea, and vomiting).; Used a 5-point scale ranging from 0 (not at all) to 4 (very much).; The scores from the 6 estrogen adverse effect items were summed to produce a single score, ranging from 0-24, with higher scores indicating higher adverse effects.	Baseline and Day 28	No
Secondary	Quality of Life (FACT-B Mean Score)	Surveyed using the multidimensional Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire; The FACT-B (version 4) questionnaire consists of 36 items with five-point scale, ranging from 0-4, where a total score ranges from 0-144 and higher scores indicate better QoL. The total FACT-B score is the sum of scores for five subscales including: physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and specific breast cancer concerns (9 items).	Day 28	No
Secondary	Frequency of Response to Re-treatment With the Same Aromatase Inhibitor That Immediately Preceded Treatment With Estradiol on Protocol.	Best overall response	12 weeks post-treatment termination	No
Secondary	Frequency of Response to Re-treatment With Estradiol for Patients Who Have a Secondary Response to an Aromatase Inhibitor After the First Response to Estradiol.		Every 3 months	No
Secondary	Overall Survival (OS)		Until patient death	No

External Links

•   Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine